Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease

被引：46

作者：

Giansanti, F ^{[1
]}

Barbera, ML

Virgili, G

Pieri, B

Emmi, L

Menchini, U

机构：

[1] Univ Florence, Dept Otoneuroophthalmol Surg Sci, Eye Clin, I-50134 Florence, Italy

[2] Univ Florence, Dept Internal Med, Immunoallergol Serv, I-50134 Florence, Italy

来源：

EUROPEAN JOURNAL OF OPHTHALMOLOGY | 2004年 / 14卷 / 05期

关键词：

Behcet disease; infliximab; retinal neovascularization; uveitis;

D O I：

10.1177/112067210401400515

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

PURPOSE. To report a case of posterior uveitis with retinal neovascularization in a patient with Behcet disease treated with infliximab. METHODS. A 50-year-old man with a history of recurrent relapses of ocular inflammation despite immunosuppressive therapy developed retinal neovascularization near the optic disk. The patient was treated with infliximab and followed up for 12 months. RESULTS. Retinal neovascularization regressed 8 months after the first anti-tumor necrosis factor (TNF) treatment and with six infusions of infliximab. The ocular inflammation resolved almost completely. CONCLUSIONS. The result suggests that anti-TNF therapy may be effective in the treatment of retinal neovascularization caused by panuveitis in Behcet disease.

引用

页码：445 / 448

页数：4

共 9 条

[1] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

[2] NEOVASCULARIZATION ASSOCIATED WITH POSTERIOR UVEITIS [J].

GRAHAM, EM ;

STANFORD, MR ;

SHILLING, JS ;

SANDERS, MD .

BRITISH JOURNAL OF OPHTHALMOLOGY, 1987, 71 (11) :826-833

[3] SIGNS AND SYMPTOMS OF UVEITIS .1. ANTERIOR UVEITIS [J].

HOGAN, MJ ;

KIMURA, SJ ;

THYGESON, P .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 1959, 47 (05) :155-170

[4] Infliximab in the treatment of refractory posterior uveitis [J].

Joseph, A ;

Raj, D ;

Dua, HS ;

Powell, PT ;

Lanyon, PC ;

Powell, RJ .

OPHTHALMOLOGY, 2003, 110 (07) :1449-1453

[5] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].

Maini, R ;

St Clair, EW ;

Breedveld, F ;

Furst, D ;

Kalden, J ;

Weisman, M ;

Smolen, J ;

Emery, P ;

Harriman, G ;

Feldmann, M ;

Lipsky, P .

LANCET, 1999, 354 (9194) :1932-1939

[6] Effect of infliximab on threatening panuveitis in Behcet's disease [J].

Muñoz-Fernández, S ;

Hidalgo, V ;

Fernández-Melón, J ;

Schlincker, A ;

Martín-Mola, E .

LANCET, 2001, 358 (9293) :1644-1644

[7]

NUSSENBLATT RB, 1985, OPHTHALMOLOGY, V92, P467

[8] Effect of infliximab on sight-threatening panuveitis in Behcet's disease [J].

Sfikakis, PP ;

Theodossiadis, PG ;

Katsiari, CG ;

Kaklamanis, P ;

Markomichelakis, NN .

LANCET, 2001, 358 (9278) :295-296

[9] Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease [J].

Triolo, G ;

Vadalà, M ;

Accardo-Palumbo, A ;

Ferrante, A ;

Ciccia, F ;

Giardina, E ;

Citarrella, P ;

Lodato, G ;

Licata, G .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (06) :560-561

← 1 →